Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ren Lin

Showing results (651-660 of 696) with videos related to

Pageof 70
Sort By:
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Experimental Hematology & Oncology|July 9, 2025
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trialKe Zhao, Ren Lin, Zhiping Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III TrialHaiyan Zhang, Zhiping Fan, Fen Huang, et al.
Journal of Medicinal Chemistry|March 29, 2012
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivoWei-Wei Li, Xiao-Yan Wang, Ren-Lin Zheng, et al.
Annals of Surgery|December 15, 2015
Postoperative Showering for Clean and Clean-contaminated Wounds: A Prospective, Randomized Controlled TrialPei-Yin Hsieh, Kuen-Yuan Chen, Hsuan-Yu Chen, et al.
Frontiers in Oncology|December 6, 2021
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC TreatmentHong-Hwa Chen, Tao-Wei Ke, Ching-Wen Huang, et al.
BMC Medicine|February 27, 2024
Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trialHaixia Fu, Xueyan Sun, Ren Lin, et al.
Developmental Cell|May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomicsG Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
Journal of Gastroenterology and Hepatology|January 4, 2008
Asia-Pacific consensus on the management of gastroesophageal reflux disease: updateKwong Ming Fock, Nicholas J Talley, Ronnie Fass, et al.
Journal of Internal Medicine|October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 studySijian Yu, Yu Zhang, Guopan Yu, et al.
Pageof 70

Showing results (651-660 of 696) with videos related to

Sort By:
Pageof 70
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Experimental Hematology & Oncology|July 9, 2025
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trialKe Zhao, Ren Lin, Zhiping Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III TrialHaiyan Zhang, Zhiping Fan, Fen Huang, et al.
Journal of Medicinal Chemistry|March 29, 2012
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivoWei-Wei Li, Xiao-Yan Wang, Ren-Lin Zheng, et al.
Annals of Surgery|December 15, 2015
Postoperative Showering for Clean and Clean-contaminated Wounds: A Prospective, Randomized Controlled TrialPei-Yin Hsieh, Kuen-Yuan Chen, Hsuan-Yu Chen, et al.
Frontiers in Oncology|December 6, 2021
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC TreatmentHong-Hwa Chen, Tao-Wei Ke, Ching-Wen Huang, et al.
BMC Medicine|February 27, 2024
Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trialHaixia Fu, Xueyan Sun, Ren Lin, et al.
Developmental Cell|May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomicsG Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
Journal of Gastroenterology and Hepatology|January 4, 2008
Asia-Pacific consensus on the management of gastroesophageal reflux disease: updateKwong Ming Fock, Nicholas J Talley, Ronnie Fass, et al.
Journal of Internal Medicine|October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 studySijian Yu, Yu Zhang, Guopan Yu, et al.
Pageof 70